AzTrials
AzTrials

Congestive Heart FailureDOBUTAPICCNCT02854254

Peripherally Inserted Central Catheter Use for Dobutamine Infusion in Heart Failure Patients

A study testing peripherally inserted central catheter and peripherally venous access in people with Congestive Heart Failure, run by InCor Heart Institute at 1 site in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In decompensation of heart failure, it may occur low cardiac output. For patients in this situation, the use of inotropic may be necessary. Prolonged intravenous infusion of inotropic agents can lead to phlebitis in peripherally venous access. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Congestive Heart Failure
What is being tested?
peripherally inserted central catheter and peripherally venous access
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteBrazil
Study dates
Dec 2012to Oct 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Advanced congestive heart failure
  • In use of intravenous inotropic
  • Platelets > 50.000 mm3
  • Left ventricular ejection fraction < 0.45

Who cannot join

  • Cardiac pacemaker or implantable defibrillator
  • Active uncontrolled systemic infection
  • Skin disease, central venous catheter

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Heart Institute (InCor), University of São Paulo

    São Paulo, São Paulo, 05403-900

Other trials in Brazil

About this study

Official title: Peripherally Inserted Central Catheters (PICC) Reduce Phlebitis Incidence in Heart Failure Patients Receiving Prolonged Intravenous Inotropic Infusion: a Randomized Trial.

In decompensation of heart failure, it may occur low cardiac output. For patients in this situation, the use of inotropic may be necessary. Prolonged intravenous infusion of inotropic agents can lead to phlebitis in peripherally venous access. On the other hand, central venous access presents complications inherent in the procedure. The peripherally inserted central catheter (PICC) may be an option in this situation. The present research project is a randomized clinical trial to evaluate the incidence of phlebitis by using the PICC in comparison to the peripheral venous access. The criteria for inclusion are: advanced congestive heart failure, in use of intravenous inotropic; platelets > 50.000 mm3 and left ventricular ejection fraction (LVEF) < 0.45. Patients will be randomized to receive the PICC or keep the peripheral venous access. The main outcome will be the occurrence of phlebitis. The sample size will be of 40 patients for each group (PICC and control). The data will be analyzed by logistic regression. Will be considered significant P 0.05.

Read the detailed description

Study design To evaluate the incidence of phlebitis using the PICC compared to peripheral venous access a randomized clinical trial was conducted in the period between 12/07/2012 and 10/02/2014, in adult cardiology department of a university hospital in Brazil. Patients were randomized into two groups permuted blocks of four. The sequence of randomization was built with random allocation blocks 4 through of random number tables. (3).The primary endpoint was occurrence of phlebitis.

Population Patients who were admitted with congestive heart failure of decompensated in use of intravenous inotropic agents were screened for eligibility to participate in this study. Inclusion criteria were: advanced congestive heart failure, use of vasoactive drugs, patients with platelet ≥50.000 mm3, left ventricular ejection fraction <0.45, upper limb venous system able for catheter insertion and central catheter peripherally inserted. Exclusion criteria were age <18, cardiac pacemaker or defibrillator, active systemic infection without treatment or without control, platelets <50.000 mm3, injury skin in cubital region and presence of central catheter.

Sample size calculation Based on pilot study data, we estimated the occurrence of phlebitis 20% in PICC group and 80% in control group. Considering statistical power of 80% and α-error in 5%, the sample size was estimated by 39 patients in each group. For more conservative estimation we defined 40 patients in each group (80 patients in total).Considering these values the sample size was 39 patients in each group in a more conservative estimate set the size in 40 patients for each group and 60% in the control group and 20% in the PICC group. In total 172 patients were evaluated, of these 86 patients did not meet the inclusion criteria and six did not agree to participate.

Ethics considerations Eligible patients were invited to participate and receive written information about the study objectives and procedures. After detailed explanations about the study if the patient agreed to participate they signed the informed consent. The study protocol was approved by the local ethics committee, and the study is in accordance with the principles set out in the Declaration of Helsinki. (1989) Intervention and endpoints Patients were divided into two groups: PICC Group and Control Group - peripheral venous access. In patients PICC group the catheter was inserted by the researcher and used to puncture technique guided by ultrasound (2). In the control group, patients were maintained with venous access by peripheral vein with flexible peripheral intravenous device and evaluation similar to the PICC group. The researcher evaluated daily the insertion site and asked the patient whether feel pain or not. The degree of phlebitis considered according to phlebitis scale Infusion Nurses Society (Table 1). Daily photo of all catheters and insertion site were performed. The patients were followed up to present the outcome, phlebitis; in his absence they were followed for ten consecutive days.

The dobutamine infusion was prescribed by responsible cardiologists well as the remaining drug therapy.

Statistical Analysis Categorical variables were expressed as number and percentage and compared between groups using the chi-square test (א 2) or Fisher's exact test. Continuous variables were expressed as mean, standard deviation and variance and compared between groups by Student's t test. Kaplan-Meir free-event curve (4) was built according the groups. Logistic regression analysis examined the predictive value of PICC Group and other variables for the occurrence of phlebitis, determining the odds ratio and its 95% confidence interval. Was considered statistically significant P <0.05. The primary analysis respected the principle of intention to treat, including only randomized patients.

Being tested
peripherally inserted central catheter, peripherally venous access
Keywords
phlebitis, catheter, congestive heart failure, dobutamine
Medical subject headings
Heart Failure, Phlebitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • peripherally inserted central catheterDevice

    peripherally inserted central catheter

  • peripherally venous accessDevice

    standard over-the-needle intravenous catheter

Study groups in NCT02854254
Study groupRoleWhat they receive
PICCExperimentalperipherally inserted central catheter
Receives: Device: peripherally inserted central catheter
ControlOtherperipherally venous access
Receives: Device: peripherally venous access

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. phlebitis by visual infusion phlebitis scale (Infusion Nurses Society)

    clinically diagnosed phlebitis by visual infusion phlebitis scale (Infusion Nurses Society) with photographic register

    Measured: 10 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2016 (estimated)
  2. Study startDec 2012
  3. Primary completionOct 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02854254
Sponsor's protocol ID
INCOR /2012
Acronym
DOBUTAPICC
Status last verified
Jul 2016
First submitted
27 Jul 2016
Last updated
3 Aug 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing peripherally inserted central catheter and peripherally venous access in people with Congestive Heart Failure, run by InCor Heart Institute at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

phlebitis by visual infusion phlebitis scale (Infusion Nurses Society) (time frame: 10 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2016; AzTrials last refreshed its copy on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in